ORTHOCLONE OKT3: First-line therapy or last option?

D. J. Norman, C. F. Shield

Research output: Contribution to journalArticle

11 Scopus citations

Abstract

ORTHOCLONE OKT3 (Ortho Pharmaceutical Corp, Raritan, NJ) a monoclonal anti-T cell antibody with in vitro immunosuppressive properties, is more effective than high-dose steroids for reversing acute renal allograft rejection. It has been used as first-line therapy for first rejection and as the last option for acute rejection, when other therapies have failed. The following report details the experience of two transplant centers on use of ORTHOCLONE OKT3 in renal transplant recipients.

Original languageEnglish (US)
Pages (from-to)949-953
Number of pages5
JournalTransplantation proceedings
Volume18
Issue number4
StatePublished - Jan 1 1986

    Fingerprint

ASJC Scopus subject areas

  • Surgery
  • Transplantation

Cite this